These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 27717148)

  • 1. A Macrocyclic Ruthenium(III) Complex Inhibits Angiogenesis with Down-Regulation of Vascular Endothelial Growth Factor Receptor-2 and Suppresses Tumor Growth In Vivo.
    Kwong WL; Lam KY; Lok CN; Lai YT; Lee PY; Che CM
    Angew Chem Int Ed Engl; 2016 Oct; 55(43):13524-13528. PubMed ID: 27717148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos.
    Golbaghi G; Pitard I; Lucas M; Haghdoost MM; de Los Santos YL; Doucet N; Patten SA; Sanderson JT; Castonguay A
    Eur J Med Chem; 2020 Feb; 188():112030. PubMed ID: 31945643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel poly-naphthol compound ST104P suppresses angiogenesis by attenuating matrix metalloproteinase-2 expression in endothelial cells.
    Ma YL; Lin SW; Fang HC; Chou KJ; Bee YS; Chu TH; Chang MC; Weng WT; Wu CY; Cho CL; Tai MH
    Int J Mol Sci; 2014 Sep; 15(9):16611-27. PubMed ID: 25244013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipalmitoylphosphatidic acid inhibits breast cancer growth by suppressing angiogenesis via inhibition of the CUX1/FGF1/HGF signalling pathway.
    Chen J; Zhou Z; Yao Y; Dai J; Zhou D; Wang L; Zhang QQ
    J Cell Mol Med; 2018 Oct; 22(10):4760-4770. PubMed ID: 30010249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of anlotinib in malignant melanoma: modulation of angiogenesis and vasculogenic mimicry.
    Yang Q; Li Q; Fan H
    Arch Dermatol Res; 2024 Jul; 316(7):447. PubMed ID: 38958761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Systems Pharmacology Approach Uncovers Wogonoside as an Angiogenesis Inhibitor of Triple-Negative Breast Cancer by Targeting Hedgehog Signaling.
    Huang Y; Fang J; Lu W; Wang Z; Wang Q; Hou Y; Jiang X; Reizes O; Lathia J; Nussinov R; Eng C; Cheng F
    Cell Chem Biol; 2019 Aug; 26(8):1143-1158.e6. PubMed ID: 31178408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A heterometallic ruthenium-gold complex displays antiproliferative, antimigratory, and antiangiogenic properties and inhibits metastasis and angiogenesis-associated proteases in renal cancer.
    Elie BT; Pechenyy Y; Uddin F; Contel M
    J Biol Inorg Chem; 2018 May; 23(3):399-411. PubMed ID: 29508136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and characterization of agnuside, a natural proangiogenic small molecule.
    Pillarisetti P; Myers KA
    Eur J Med Chem; 2018 Dec; 160():193-206. PubMed ID: 30340142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functionalized azirine based scaffolds as endothelin inhibitors for the selective anti-angiogenic activity.
    Singh H; Satish N; Babu TR; Singh A; Yadav B; Singh SK; Wahajuddin M; Siddiqui MI; Jagavelu K; Sudhakar G
    Eur J Med Chem; 2024 Aug; 274():116510. PubMed ID: 38843585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciphering the anticancer mechanisms of sunitinib.
    Pal SK; Figlin RA; Yu H
    Cancer Biol Ther; 2010 Oct; 10(7):712-4. PubMed ID: 20716960
    [No Abstract]   [Full Text] [Related]  

  • 11. Ruthenium-dihydroartemisinin complex: a promising new compound for colon cancer prevention via G1 cell cycle arrest, apoptotic induction, and adaptive immune regulation.
    Wang CZ; Wan C; Li CH; Liang GG; Luo Y; Zhang CF; Zhang QH; Ma Q; Wang AH; Lager M; Jiang TL; Hou L; Yuan CS
    Cancer Chemother Pharmacol; 2024 May; 93(5):411-425. PubMed ID: 38191768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Half-Sandwich Ruthenium(II) (N^N) Complex: Inducing Immunogenic Melanoma Cell Death in Vitro and in Vivo.
    Xu Z; Xu M; Wu X; Guo S; Tian Z; Zhu D; Yang J; Fu J; Li X; Song G; Liu Z; Song X
    ChemMedChem; 2023 Aug; 18(16):e202300131. PubMed ID: 37226330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual FGFR-targeting and pH-activatable ruthenium-peptide conjugates for targeted therapy of breast cancer.
    Franco Machado J; Sá M; Pires I; da Silva MT; Marques F; Coelho JAS; Mendes F; Piedade MFM; Machuqueiro M; Jiménez MA; Garcia MH; Correia JDG; Morais TS
    Dalton Trans; 2024 May; 53(18):7682-7693. PubMed ID: 38573236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of ruthenium(II)-arene complex [Ru(η
    Berndsen RH; Weiss A; Abdul UK; Wong TJ; Meraldi P; Griffioen AW; Dyson PJ; Nowak-Sliwinska P
    Sci Rep; 2017 Feb; 7():43005. PubMed ID: 28223694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-coating cRGD-modified bovine serum albumin enhanced the anti-tumor angiogenesis of siVEGF-loaded chitosan-based nanoparticles by manipulating the protein corona composition.
    Wu Z; Yuan C; Xia Q; Qu Y; Yang H; Du Q; Xu B
    Int J Biol Macromol; 2024 May; 267(Pt 2):131546. PubMed ID: 38614172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent Ruthenium-Ferrocene Bimetallic Antitumor Antiangiogenic Agent That Circumvents Platinum Resistance: From Synthesis and Mechanistic Studies to
    M M; Gadre S; Chhatar S; Chakraborty G; Ahmed N; Patra C; Patra M
    J Med Chem; 2022 Dec; 65(24):16353-16371. PubMed ID: 36459415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioresponsive cancer-targeted polysaccharide nanosystem to inhibit angiogenesis.
    Yang F; Fang X; Jiang W; Chen T
    Int J Nanomedicine; 2017; 12():7419-7431. PubMed ID: 29066892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo.
    Myers T; Chengedza S; Lightfoot S; Pan Y; Dedmond D; Cole L; Tang Y; Benbrook DM
    Invest New Drugs; 2009 Aug; 27(4):304-18. PubMed ID: 18802666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel.
    Steins A; Ebbing EA; Pistorius MCM; Waasdorp C; Krishnadath KK; Medema JP; Wilmink JW; Mathôt RAA; Bijlsma MF; van Laarhoven HWM
    Drug Deliv; 2017 Nov; 24(1):1801-1810. PubMed ID: 29172757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cobalt(III)-Macrocyclic Scaffolds with Anti-Cancer Stem Cell Activity.
    Fang J; Gerschel P; Singh K; Apfel UP; Suntharalingam K
    Molecules; 2024 Jun; 29(12):. PubMed ID: 38930809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.